Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

被引：0
|
作者：
Park, Keunchil
Lee, Jong-Seok
Lee, Ki Hyeong
Kim, Joo-Hang
Min, Young Joo
Cho, Jae Yong
Han, Ji-Youn
Kim, Bong-Seog
Kim, Jin-Soo
Lee, Dae Ho
Kang, Jin Hyoung
Cho, Eun Kyung
Jang, In-Jin
Jung, Jina
Kim, Hyo-Yeon
Sin, Hui Jung
Son, Jeewoong
Woo, Jong Soo
Kim, Dong-Wan
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Oncol, Seoul, South Korea
[2] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul Natl Unvers,Bundang Hosp, Soengnam, South Korea
[3] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[4] Yonsei Canc Ctr, Seoul, South Korea
[5] Ulsan Univ Hosp, Dept Med, Ulsan, South Korea
[6] Gangnam Severance Hosp, Seoul, South Korea
[7] Natl Canc Ctr, Goyang, South Korea
[8] VHS Med Ctr, Seoul, South Korea
[9] Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea
[10] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[11] Seoul St Marys Hosp, Seoul, South Korea
[12] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Hematol & Oncol, Inchon, South Korea
[13] Seoul Natl Univ Hosp, Dept Clin Pharmacol, Seoul 110744, South Korea
[14] Hanmi Pharmaceut Co Ltd, Seoul, South Korea
[15] Seoul Natl Univ Hosp, Seoul 110744, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8084
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A RETROSPECTIVE ANALYSIS OF THE CLINICAL RESPONSES TO EGFR-TYROSINE KINASE INHIBITOR (EGFR-TKI) CONTINUOUS TREATMENT BEYOND SINGLE SITE DISEASE PROGRESSION IN METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WHO BENEFITED FROM PRIOR EGFR-TKI THERAPY
    Parra, Hector J. Soto
    Chiari, Rita
    Bearz, Alessandra
    Cavina, Raffaele
    Spadaro, Pietro
    Latteri, Fiorenza
    Bordonaro, Roberto
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1254 - S1254
  • [32] The efficacy and safety of EGFR-TKI combined with chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR co-mutation with other oncogenic alterations.
    Yu, Qitao
    Jiang, Wei
    Zeng, Aiping
    Qiu, Hongtu
    Qi, Chuang
    Zhang, Xing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Effect of Antibiotic Exposure on the Efficacy of EGFR TKIs in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
    Pengnoraphat, B.
    Saichaemchan, S.
    Thambamroong, T.
    Phavirunsiri, J.
    Peechatanan, K.
    Prasongsook, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S623 - S623
  • [34] EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
    Michelon, Isabella
    Vilbert, Maysa
    Castro, Caio Ernesto do Rego
    Stecca, Carlos
    Dacoregio, Maria Inez
    Rizzo, Manglio
    de Lima, Vladmir Claudio Cordeiro
    Cavalcante, Ludimila
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (07):
  • [35] Preclinical study of olmutinib (HM61713) with optimal dosing in ectopic and metastatic mouse model of EGFR-mutant (T790M-positive) non-small cell lung cancer (NSCLC)
    Lee, H. J.
    Yu, H.
    Ha, Y.
    Byun, J-Y.
    Oh, J.
    Song, T.
    Hong, S.
    Kim, E. Y.
    Jang, S-Y.
    Kim, G. Y.
    Kim, Y. H.
    Suh, K. H.
    Kwon, S. C.
    Kim, S-J.
    ANNALS OF ONCOLOGY, 2017, 28 : 132 - 132
  • [36] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Dickgreber, Nicolas J.
    Halmos, Balazs
    Hirsh, Vera
    Hochmair, Maximilian J.
    Levy, Benjamin Philip
    De Marinis, Filippo
    Mok, Tony
    O'Byrne, Kenneth
    Okamoto, Isamu
    Schuler, Martin H.
    Sebastian, Martin
    Shah, Riyaz N. H.
    Tan, Eng-Huat
    Yamamoto, Nobuyuki
    Marten, Angela
    Massey, Dan
    Wind, Sven
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Passaro, A.
    Yang, J. C.
    Ahn, M.
    Dickgreber, N. J.
    Halmos, B.
    Hirsh, V.
    Hochmair, M. J.
    Levy, B. P.
    de Marinis, F.
    Mok, T.
    O'Byrne, K.
    Okamoto, I.
    Schuler, M.
    Sebastian, M.
    Shah, R.
    Tan, E.
    Yamamoto, N.
    Maerten, A.
    Wind, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 77 - 77
  • [38] Phase I/II Study of AC0010, Mutant Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation
    Wu, Yi Long
    Zhou, Qing
    Liu, Xiaoqing
    Zhang, Li
    Zhou, Jianying
    Wu, Lin
    An, Tongtong
    Cheng, Ying
    Zheng, Xin
    Hu, Bei
    Jiang, Ji
    Fang, Xin
    Xu, Wanhong
    Xu, Xiao
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S437 - S438
  • [39] Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
    Su, P-L.
    Wu, Y-L.
    Chang, W-Y.
    Su, W-C.
    Yang, S-C.
    Lin, C-C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
    Su, Po-Lan
    Wu, Yi-Lin
    Chang, Wei-Yuan
    Ho, Chung-Liang
    Tseng, Yau-Lin
    Lai, Wu-Wei
    Su, Wu-Chou
    Lin, Chien-Chung
    Yang, Szu-Chun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
12345